Literature DB >> 18386213

SSRI adverse events: how to monitor and manage.

Tanya K Murphy1, Ana Segarra, Eric A Storch, Wayne K Goodman.   

Abstract

Antidepressants are efficacious for pediatric major depressive disorder, obsessive compulsive disorder (OCD), and non-OCD anxiety disorders. Antidepressants should be used in an evidence-based fashion, with frequent monitoring for side effects, especially when initiating treatment and adjusting dosage. With diligence to appropriate prescribing and monitoring, the benefits of therapy outweigh the potential of treatment related risk.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18386213     DOI： 10.1080/09540260801889211

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN： 0954-0261


  21 in total

1.  Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile.

Authors:  Jeannette M Reid; Eric A Storch; Tanya K Murphy; Danielle Bodzin; P Jane Mutch; Heather Lehmkuhl; Michael Aman; Wayne K Goodman
Journal:  Child Youth Care Forum       Date:  2010-02-04

2.  Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.

Authors:  Adam M Reid; Joseph P H McNamara; Tanya K Murphy; Andrew G Guzick; Eric A Storch; Wayne K Goodman; Gary R Geffken; Regina Bussing
Journal:  J Psychiatr Res       Date:  2015-10-14       Impact factor: 4.791

3.  Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.

Authors:  Wendi E Marien; Eric A Storch; Gary R Geffken; Tanya K Murphy
Journal:  Cogn Behav Pract       Date:  2009-08

4.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

5.  A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION.

Authors:  Joseph F McGuire; John Piacentini; Adam B Lewin; Erin A Brennan; Tanya K Murphy; Eric A Storch
Journal:  Depress Anxiety       Date:  2015-06-30       Impact factor: 6.505

6.  Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD.

Authors:  Regina Bussing; Tanya K Murphy; Eric A Storch; Joseph P H McNamara; Adam M Reid; Cynthia W Garvan; Wayne K Goodman
Journal:  Psychiatry Res       Date:  2012-09-29       Impact factor: 3.222

7.  A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Eric A Storch; Tanya K Murphy; Wayne K Goodman; Gary R Geffken; Adam B Lewin; Aude Henin; Jamie A Micco; Susan Sprich; Sabine Wilhelm; Michael Bengtson; Daniel A Geller
Journal:  Biol Psychiatry       Date:  2010-12-01       Impact factor: 13.382

8.  Clinical management of behavioral characteristics of Prader-Willi syndrome.

Authors:  Alan Y Ho; Anastasia Dimitropoulos
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

9.  Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.

Authors:  Eric A Storch; Sabine Wilhelm; Susan Sprich; Aude Henin; Jamie Micco; Brent J Small; Joseph McGuire; P Jane Mutch; Adam B Lewin; Tanya K Murphy; Daniel A Geller
Journal:  JAMA Psychiatry       Date:  2016-08-01       Impact factor: 21.596

Review 10.  Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome.

Authors:  Alessandro S De Nadai; Marc S Karver; Tanya K Murphy; Mark A Cavitt; Jeffrey L Alvaro; Michael Bengtson; Saundra Stock; Andrew C Rakhshani; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-29       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.